S2 Ep99: October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice
In this update episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, opens with regulatory news.
The FDA accepted uniQure’s application for AMT-130, a gene therapy for Huntington disease, under priority review. An advisory committee meeting is tentatively planned, and a decision is possible in May 2027. AV-1959R (Nuravax, Inc), an investigational amyloid-β vaccine, received fast track designation for preventing Alzheimer disease in cognitively unimpaired individuals with biomarker evidence of amyloid pathology. FDA decisions are expected in November on asundexian (Bayer HealthCare)…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.